ArticleBiochemistry2009
Characterization of an AM404 analogue, N-(3-hydroxyphenyl)arachidonoylamide, as a substrate and inactivator of prostaglandin endoperoxide synthase.
Article in Biochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Systematic Review of Systemic and Neuraxial Effects of Acetaminophen in Preclinical Models of Nociceptive Processing.Journal of pain research · 2021Review
- AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity.Journal of neuroinflammation · 2017Article
- Structural basis of fatty acid substrate binding to cyclooxygenase-2.The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
N-(4-Hydroxyphenyl)arachidonoylamide (AM404) is an inhibitor of endocannabinoid inactivation that has been used in cellular and animal studies. AM404 is a derivative of arachidonic acid and has been reported to inhibit arachidonate oxygenation by prostaglandin endoperoxide synthase-1 and -2 (PGHS-1 and -2, respectively). While examining the structural requirements for inhibition of PGHS, we discovered that the meta isomer of AM404, N-(3-hydroxyphenyl)arachidonoylamide (3-HPAA), is a substrate for purified PGHS. PGHS-2 efficiently oxygenated 3-HPAA to prostaglandin and hydroxyeicosatetraenoate products. No oxidation of the phenolamide moiety was observed. 3-HPAA appeared to be converted by PGHS-1 in a similar manner; however, conversion was less efficient than that by PGHS-2. PGHS-2 was selectively, dose-dependently, and irreversibly inactivated in the presence of 3-HPAA. Complete inactivation of PGHS-2 was achieved with 10 muM 3-HPAA. Preliminary characterization revealed that 3-HPAA inactivation did not result from covalent modification of PGHS-2 or damage to the heme moiety. These studies provide additional insight into the structural requirements for substrate metabolism and inactivation of PGHS and report the first metabolism-dependent, selective inactivator of PGHS-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.